glp 1 weight loss medications GLP-1 Drugs from the Gray Market GLP-1 Drug Savings: A Complete
Description
A recent nationwide estimate of obesity indicated that 42% of adults aged 20 and over are obese
Recent trials have shown: Up to 20% body weight reduction with weekly GLP-1 agonists (Wilding et al., NEJM) Improvements in HbA1c, fasting glucose, and cardiovascular outcomes (Marso et al., NEJM) This drug class is now widely used for: Obesity (with or without diabetes) Type 2 diabetes PCOS-related insulin resistance Metabolic syndrome Common Side Effects and Patient Concerns Despite their benefits, GLP-1 agonists are not without risks or drawbacks
doi: 10.1146/annurev.physiol.59.1.257 23 SchjoldagerBMortensenPEMyhreJChristiansenJHolstJJ
It is not an injection, not a peptide, and not a GLP-1 receptor agonist
Denied by Insurance
Short-acting agents like exenatide often cause more gastroparesis (slow gastric emptying), while long-acting ones like dulaglutide may be better tolerated
